Loading...
Loading...
According to a research report released earlier today, Auriga has downgraded Anthera Pharmaceuticals Inc.
ANTH from Hold to Sell based on excessive valuation.
Auriga commented in the report, “We also note interesting competition from upstart CareCloud (private) which boasts a more flexible approach to the revenue cycle and a much friendlier and intuitive user interface. Given the stock's 50% move since its Analyst Day in December, on what we perceive to be weakening fundamentals, we recommend investors take profits as we envision 25% downside from current levels. Our $57 price target is unchanged.”
Anthera Pharmaceuticals closed yesterday at $75.65.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in